New Targets, New Agents, New Combinations: Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma

This activity is not certified for credit
Release Date:
 August 5, 2021
Expiration Date: August 4, 2022

Jointly provided by Postgraduate Institute for Medicine and Bio Ascend, LLC

Activity Overview
Hear from 3 renowned experts actively engaged in the care of patients with multiple myeloma from an 
independent satellite symposium that took place following the #ASCO21 Meeting.  

Target Audience
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives
After participating in this activity, participants should be better able to:

  • Evaluate treatment approaches for patients with relapsed and/or refractory MM specifically the decision to include a monoclonal antibody or antibody-drug conjugate, and combination with other agents for triplet therapy
  • Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with MM
  • Discuss the results of clinical trials that are investigating emerging novel agents in patients with MM

Method of Participation
There are no fees for participating in this activity

Topics Presented

 --Evolving Profile of a Patient with Relapsed/Refractory MM
              Therapies recently moved to the frontline setting and what it means for rrMM care

 --Clinical Experience With Newly Approved Therapies
               Review of Recent Clinical Trial Readouts

 --Choosing the Right Combination Therapy
               Triplet vs Doublet Therapy

 --How to Manage Novel AE Profiles
               Working with Other Specialties
               Dosing and Schedule Adjustments

 --Panel Discussion and Audience Q&A

Noopur Raje, MD
Professor of Medicine, Harvard Medical School

Director, Multiple Myeloma Program, Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Consultant /Advisory Board: Celgene, Takeda, Amgen, Novartis, Janssen, BMS, Merck, Pfizer, Bluebird, Caribou Biosciences, Immuneel Therapeutics
Research Funding: Bluebird Bio

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen),
City of Hope Cancer Center

Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University

Consulting Fees: Amgen Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi

Krina Patel, MD
Associate Professor, Department and Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Fees: Bristol Myers Squibb Company, Janssen, Oncopeptides, Pfizer Inc.
Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: Bio Ascend, Curio Science, Dava Oncology, Research to Practice
Contracted Research: Bristol Myers Squibb Company, Cellectis, Poseida, Precison BioSciences, Nektar, Takeda

Disclosure of Commercial Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

This activity is supported by independent educational grants from Oncopeptides and Sanofi Genzyme.

Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.